Curis, Inc. (CRIS)

1.78
0.06 3.26
NASDAQ
Prev Close 1.84
Open 1.81
Day Low/High 1.76 / 1.87
52 Wk Low/High 0.60 / 5.20
Volume 91.51K
Exchange NASDAQ
Shares Outstanding 33.15B
Market Cap 58.01M
Div & Yield N.A. (N.A)
Curis Reports Second Quarter 2014 Financial Results

Curis Reports Second Quarter 2014 Financial Results

Management to Host Conference Call Today at 9:00 a.m. EDT

Curis Announces Re-Initiation Of Patient Dosing In CUDC-427 Monotherapy Clinical Trial

Curis Announces Re-Initiation Of Patient Dosing In CUDC-427 Monotherapy Clinical Trial

- Expansion Phase to Include Patients With Ovarian Cancer and Certain Hematologic Malignancies -

CRIS: Insiders vs. Shorts

CRIS: Insiders vs. Shorts

The most recent short interest data was recently released by the NASDAQ for the 04/15/2014 settlement date, and Curis Inc is one of the most shorted stocks of the Russell 3000, based on 8.86 "days to cover" versus the median component at 4.95. There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded.

Curis Reports First Quarter 2014 Financial Results

Curis Reports First Quarter 2014 Financial Results

Management to Host Conference Call Today at 9:00 a.m. EDT

First Week of December 20th Options Trading For Curis (CRIS)

First Week of December 20th Options Trading For Curis (CRIS)

Investors in Curis Inc saw new options begin trading this week, for the December 20th expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 229 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Curis Announces U.S. Patent Issuance Covering CUDC-907 Composition-of-Matter

Curis Announces U.S. Patent Issuance Covering CUDC-907 Composition-of-Matter

- Dual HDAC and PI3K Inhibitor in Ongoing Phase 1 Study in Patients With Relapsed/ Refractory Lymphoma and Multiple Myeloma -

Curis And Debiopharm Group(TM) Report Preclinical Data For Debio 0932 At AACR Annual Meeting 2014

Curis And Debiopharm Group(TM) Report Preclinical Data For Debio 0932 At AACR Annual Meeting 2014

Debio 0932 Demonstrated Anti-Tumor Activity and Synergy With Various SOC Agents in In Vitro and Xenograft Models of NSCLC and RCC

Biotech Leads the Way as Stocks Move Higher

Biotech Leads the Way as Stocks Move Higher

Several positive headlines for various drug companies combined to push the biotech sector higher and bringing the other indices along with it.

Curis Announces Removal Of FDA Partial Clinical Hold On CUDC-427

Curis Announces Removal Of FDA Partial Clinical Hold On CUDC-427

- Curis Expects to Reinitiate Enrollment in Single Agent Phase 1 Study of CUDC-427 in Patients With Solid Tumors or Lymphoma -

Interesting CRIS Put Options For May 17th

Interesting CRIS Put Options For May 17th

Investors in Curis Inc saw new options begin trading this week, for the May 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the CRIS options chain for the new May 17th contracts and identified the following put contract of particular interest.

Interesting CRIS Put Options For April 19th

Interesting CRIS Put Options For April 19th

Investors in Curis Inc saw new options begin trading this week, for the April 19th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the CRIS options chain for the new April 19th contracts and identified the following put contract of particular interest.

Curis Reports Fourth Quarter And Year-End 2013 Financial Results

Curis Reports Fourth Quarter And Year-End 2013 Financial Results

-- Management to Host Conference Call Today at 9:00 a.m. EST --

CRIS: Insiders vs. Shorts

CRIS: Insiders vs. Shorts

The most recent short interest data was recently released by the NASDAQ for the 01/15/2014 settlement date, and Curis Inc is one of the most shorted stocks of the Russell 3000, based on 11.55 "days to cover" versus the median component at 3.97. There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded.

TheStreet Quant Rating: D- (Sell)